OCTOBER 2023LIFE SCIENCES REVIEW7Kazuto Yamada, Senior Director, Head of Clinical Development Planning and SupervisingFive R&D Functions,Otsuka PharmaceuticalEurope has long been at the forefront of Next-Generation Sequencing (NGS) technologies, pioneering advancements in genomics and bolstering their comprehension of genetics and genomics. The collective efforts of European institutions, universities, and biotechnology enterprises have left an indelible mark on NGS innovation, ushering in enhancements in speed and precision, cost reductions, and the pioneering of single-cell sequencing methodologies. These techniques hold profound implications for delving into the intricacies of diseases at the cellular level and propelling the field of regenerative medicine forward. Furthermore, the fusion of genomics with other "omics" data has gained increasing prominence, facilitating the unearthing of novel biomarkers and therapeutic targets. As the trajectory suggests, European researchers are poised to maintain their leadership in NGS innovations, with the integration of artificial intelligence and machine learning poised to revolutionise the pace and accuracy of analyses in this dynamic field.In this edition of Life Sciences Review, we present an insightful glimpse into the world of next-generation sequencing company in Europe, renowned for their unwavering dedication to precision and excellence. Among the featured companies, QIAGEN stands out as a prominent player, focusing on harnessing the power of small RNA molecules in liquid biopsy for an exceedingly precise diagnostic approach. Central to QIAGEN's core mission is a visionary commitment to enhancing the quality of life, a commitment translated into action by providing innovative samples to insight solutions. The magazine further highlights insightful viewpoints shared by prominent experts in the field of genomics: Samir Ounzain, a scientist specialising in regulatory RNAs at HAYA Therapeutics, and Stefano Ferrara, the Director of Clinical Science at BeiGene. They underscore the critical importance of continuous investment in research and development to secure a competitive advantage within the ever-evolving global genomics landscape. We hope these valuable insights from industry leaders featured in this edition will assist you in making informed decisions for your businesses.Let us know your thoughts.EDITORIALPrecision Medicine Advances with Europe's NGSCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsOctober - 06- 2023, Vol 04, Issue -45 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersRonald DonovanVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 6 | Page 8 >